Insights

Filters   Sort By Newest  
Newest Oldest Title
Updating results

Showing results 1 - 24 of 101 Results per page:

No results found.

  • Advertising, Marketing & Regulatory
  • Artificial Intelligence
  • Automotive
  • Cannabis
  • Chemical
  • Chemical AI
  • Cleantech
  • Copyright & Digital Media
  • Electrical & Computer Technology
  • Financial Technology
  • Industrial Designs
  • IP Management & Strategic Counselling
  • Licensing & Transactions
  • Life Sciences
  • Litigation & Dispute Resolution
  • Mechanical & Industrial Processes
  • Medical Technology
  • Nanotechnology
  • Oil & Gas
  • Patents
  • Plant Breeders’ Rights
  • Privacy & Data Protection
  • Psychedelics
  • Quantum Technologies
  • Trademarks
  • Nicholas Aitken
  • Arvin Angue
  • Adam Aucoin
  • William Audet
  • Ryan Baker
  • Christie J. C. Bates
  • Stephen Beney
  • Brett Benham
  • Daniel Bereskin
  • Janice M. Bereskin
  • Shaivi Bhatt
  • Adam Bierylo
  • Paul David Blizzard
  • Adam Bobker
  • Jennifer Boothby
  • Chantalle Briggs
  • Jonathan G. Burkinshaw
  • Don Cameron
  • Isi Caulder
  • Brigitte Chan
  • Wynnie Chan
  • Mina Chana
  • Herman Cheung
  • Iris Cheung
  • Kyle Classen
  • Toba Cooper
  • Noel Courage
  • Carmela De Luca
  • Ryan De Vries
  • Reshika Dhir
  • Meghan Dillon
  • Terry Edwards
  • Prudence Ariella Etkin
  • Michael Fenwick
  • Patricia Folkins
  • Cameron Gale
  • Matthew John Graff
  • Louis-Pierre Gravelle
  • Micheline Gravelle
  • Gail Hung
  • Nicole Hunter
  • Jason Hynes
  • Alissa Hyppolite
  • Nyrie Israelian
  • Susan J. Keri
  • Denis V. Keseris
  • Ellen Kiernan
  • Simone Knott
  • Ray Kovarik
  • Victor Krichker
  • Dominique Lambert
  • François Larose
  • Julia London
  • Maddie Lynch
  • Joanna Ma
  • R. Scott MacKendrick
  • Don MacOdrum
  • Jennifer Manley
  • Sandra Marone
  • Andrew McIntosh
  • Melissa J. McKeon
  • Ian McMillan
  • Philip C. Mendes da Costa
  • Hailey Min
  • David Morrison
  • Luba Naiberger
  • Paige Newman
  • Andrea Ngo
  • Tony Orsi
  • Ainslie Parsons
  • Chelsea Pham
  • Justin Philpott
  • Scott Pundsack
  • James Raakman
  • Mohamed Rahal
  • Bhupinder Randhawa
  • Sunil Rao
  • Kimberly Ren
  • Coralee Ridder
  • Mark L. Robbins
  • Jane Sargeant
  • Timothy Sinnott
  • Parnian Soltanipanah
  • Josh Spicer
  • David St-Martin
  • Kate Stewart-Tiralongo
  • Robert Storey
  • Jessica R. Sudbury
  • Melanie Szweras
  • Benjamin Todd
  • Andrea Uetrecht
  • Charles Wang
  • Maria Wei
  • Tamara Céline Winegust
  • Shuo Xing
  • Leanne Young
  • Jennie Yum
  • Previous 30 days
  • Previous 90 days
  • Previous year
  • From to

Explore our Insights

January 10, 2023
Canadian Grant Agency Raises Clinical Trial Reporting Requirements
By Maddie Lynch and Noel Courage 
›
December 12, 2022
Getting Transparent About Transparency: Canadian Registration and Reporting of Clinical Trials
By Noel Courage and Maddie Lynch
›
December 2, 2022
The Role of IP Management in Product Development
By Luba Naiberger and Noel Courage 
›
November 10, 2022
PMPRB Regulations Saga Coming to an End? New Draft Guidelines Issued
By Nyrie Israelian, Parnian Soltanipanah, Melanie Szweras, Noel Courage 
›
August 26, 2022
Is this Drug Safe and Effective Enough? Canadian Regulators Wade into Alzheimer’s Drug Controversy
By Noel Courage and Iris Cheung
›
June 27, 2022
One person’s trash is another person’s treasure – Where France goes, will others follow?
By Noel Courage and Luca Manfredi
›
May 5, 2022
What’s it Worth? Valuation of IP
By Noel Courage and Keon Coleman
›
April 22, 2022
Canada Drops its Most Controversial Patented Drug Pricing Amendments
By Nyrie Israelian and Noel Courage
›
April 1, 2022
Supreme Court of Canada Takes a Pass on Patented Drug Price Dispute
By: Nyrie Israelian and Noel Courage
›
March 18, 2022
Ontario Government Launches IP Agency to Support Innovators and Increase IP Value
By: Mitchel Fleming, Tony Orsi and Noel Courage
›
March 9, 2022
2021 Year in Review: COVID-19
By Noel Courage and Herman Cheung
›
February 28, 2022
Proposed Canadian Drug Pricing Rules Delayed by Feds and Battered by Courts 
By Noel Courage and Nyrie Israelian
›

Subscribe to our newsletter

You can unsubscribe at any time. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

December 9, 2021
Plot Twist: New Exceptions Water Down Ban on Employee Non-Compete Agreements
By Noel Courage
›
November 25, 2021
Licensing of COVID-19 Diagnostic IP to Facilitate Fast Access in the Third World  
By Noel Courage
›
November 17, 2021
Medicines Patent Pool Gets Big Wins in Accessing Breakthrough COVID-19 Drugs for the Third World
By Noel Courage 
›
November 16, 2021
One Person’s Trash is Another Person’s Treasure Part IV: The Right to Repair Movement – U.K. Update
By Bonnie Hassanzadeh and Noel Courage
›
November 9, 2021
A Healthy Dose of Skepticism From Regulators Leads to a Safe and Effective Dose of COVID-19 Drugs and Vaccines
By Noel Courage and Iris Cheung
›
October 26, 2021
Use of Employee Non-compete Agreements About to Become Void in Ontario
By Noel Courage
›
October 7, 2021
One Person’s Trash is Another Person’s Treasure Part III: The Right to Repair Movement in the European Union
By Noel Courage and Bonnie Hassanzadeh
›
September 15, 2021
One Person’s Trash is Another Person’s Treasure Part II: The Right to Repair Movement in the United States
By Noel Courage and Bonnie Hassanzadeh 
›
August 6, 2021
Proposed COVID-19 Vaccine Patent Waiver Making Slow Progress
By Noel Courage and Luca Manfredi
›
August 5, 2021
Canadian Drug Price Review Board Reined In
By Noel Courage and Nyrie Israelian
›
June 25, 2021
One Person’s Trash is Another Person’s Treasure: The Interaction of IP and the Right to Repair
By Noel Courage and Bonnie Hassanzadeh
›
May 21, 2021
Getting Behind COVID-19 Vaccine Innovators (Summary Version)
By Noel Courage
›
Loading...
Load Results 25 - 48 of 101

Showing results 1 - 24 of 101 Results per page:

No results found.

Subscribe to our newsletter

You can unsubscribe at any time. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

This site is registered on wpml.org as a development site.